Oculgen
Latest round
- Series B
Last raised
- Dec 2025
Total raised
- $44M
Investors
- 7
About Oculgen
, dba Oculgen, operates as a biopharmaceutical technology company, focusing on innovative macromolecular ophthalmic therapies. The founder, Jiongguang Chen, is a PhD of University of Arizona and a postdoctoral fellow of University of California. The company has set up a R&D center in Zhuhai. It is recognized as a Suzhou Leading Entrepreneurial Talent Enterprise, and its core product OCUL10 has obtained clinical approval from FDA and CDE. Oculgen specializes in the research and development of innovative ophthalmic therapies, particularly focusing on large-molecule drugs for treating serious eye diseases. The company addresses conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and glaucoma. The company generates revenue by developing innovative dual-target, triple-effect antibodies that can be used to treat non-macular degeneration (nAMD), diabetic macular edema (DME) and geographic atrophy (GA). And its other pipelines under development are expected to submit INDs in China and the United States by the end of 2025.
Who invested in Oculgen
7 investors across 2 rounds
See all investors in Oculgen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Oculgen
Who invested in Oculgen?
Oculgen has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Oculgen raised?
Oculgen has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Oculgen last raise money?
Oculgen's most recent round on record is a Series B, in Dec 2025.
What does Oculgen do?
, dba Oculgen, operates as a biopharmaceutical technology company, focusing on innovative macromolecular ophthalmic therapies.
Where is Oculgen headquartered?
Oculgen is headquartered in Shenzhen, China.
Which VCs invest in companies like Oculgen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Oculgen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Oculgen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.